TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21144456

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acupuncture with co-interventions (including NSAIDs or analgesics)
Number of subjects: 18
Study: 19195455

Group type: EXPERIMENTAL
Intervention: Darunavir (DRV/r) 600/100 mg two times a day
Number of subjects: 595

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 595
Study: 16606546

Group type: EXPERIMENTAL
Intervention: Nebulized furosemide (10 mg/m2) plus nebulized salbutamol (0.15 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nebulized saline (placebo) plus nebulized salbutamol (0.15 mg/kg)
Number of subjects: 0
Study: 12846772

Group type: EXPERIMENTAL
Intervention: 300 mg of iron sucrose administered intravenously over two hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administered intravenously over two hours
Number of subjects: 20
Study: 10843158

Group type: EXPERIMENTAL
Intervention: PTH (hPTH 1-34, 200 U in saline over 5 min)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8976035

Group type: EXPERIMENTAL
Intervention: Different blood cardioplegia modes (5 types)
Number of subjects: 109
Study: 1451726

Group type: EXPERIMENTAL
Intervention: MK-571 (75 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-571 (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-571 (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-571 (all doses)
Number of subjects: 12
Study: 6391005

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg and Nifedipine 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30831456

Group type: EXPERIMENTAL
Intervention: Triangle trocar configuration
Number of subjects: 113

Group type: COMPARATOR
Intervention: Midline trocar configuration
Number of subjects: 113
Study: 28557857

Group type: EXPERIMENTAL
Intervention: 5-mg melatonin supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 27491280

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg plus Dapagliflozin 10 mg coadministered
Number of subjects: 42
Study: 24988227

Group type: EXPERIMENTAL
Intervention: Outdoor adventure program (6-day program including kayaking, surfing, or climbing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outdoor adventure program (6-day program for participants who took part for the second time)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 22479985

Group type: EXPERIMENTAL
Intervention: Combined orthodontic/regenerative therapy with immediate orthodontic tooth movement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined orthodontic/regenerative therapy with delayed orthodontic tooth movement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Regenerative therapy alone (control group)
Number of subjects: 15
Study: 19690902

Group type: EXPERIMENTAL
Intervention: Fluoride desensitizer (Aqua‐Prep F)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Triclosan desensitizer (Seal&Protect)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (VC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Variolink II (V)
Number of subjects: 90
Study: 17609397

Group type: EXPERIMENTAL
Intervention: GHRP-2 (100 microg dose administered intravenously)
Number of subjects: 135
Study: 16296916

Group type: EXPERIMENTAL
Intervention: Homeopathic remedies
Number of subjects: 0

Group type: COMPARATOR
Intervention: RCT methodology
Number of subjects: 0
Study: 11892709

Group type: EXPERIMENTAL
Intervention: Periarticular injection of methylprednisoloneacetate and lidocaine (MP group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isotonic sodium chloride and lidocaine (non-MP group)
Number of subjects: 24
Study: 10780243

Group type: EXPERIMENTAL
Intervention: Ethanol (0.2, 0.4 or 0.8 g/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25 or 0.5 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8546280

Group type: EXPERIMENTAL
Intervention: 5 cmH2O pressure support ventilation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 cmH2O pressure support ventilation
Number of subjects: 16
Study: 1951242

Group type: EXPERIMENTAL
Intervention: Haptoglobin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ethanolamine oleate (Control)
Number of subjects: 37
Study: 6167117

Group type: EXPERIMENTAL
Intervention: Aspirin dipyridamole combination
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31810219

Group type: EXPERIMENTAL
Intervention: Apple preload and rice (PA+R)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rice with sugar solution preload (PSS+R)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rice (control)
Number of subjects: 18
Study: 29957283

Group type: EXPERIMENTAL
Intervention: Task-oriented daily physical activity (DPA) assessed using interviewer-administered recall questionnaire (DPA-R) in Cohort 1
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Task-oriented daily physical activity (DPA) assessed using self-administered diary-format daily checklist (DPA-C) in Cohort 2
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Composite score of 6 DPA items (putting on shoes, showering, washing hair, walking for exercise, frequency of walks >10 min, walking on an incline)
Number of subjects: 284
Study: 26874291

Group type: EXPERIMENTAL
Intervention: Exposure based treatment
Number of subjects: 0
Study: 24882460

Group type: EXPERIMENTAL
Intervention: New device for autoinflation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: New device for autoinflation (after crossover)
Number of subjects: 45
Study: 22760558

Group type: EXPERIMENTAL
Intervention: Almond-containing diet (42 g/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Almond-containing diet (84 g/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Controlled diet (0 g/d)
Number of subjects: 18
Study: 19896213

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17166688

Group type: EXPERIMENTAL
Intervention: Hypoxic abdominal perfusion (HAP) with mitomycin C 30mg/m² and cisplatin 60mg/m²
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hypoxic abdominal perfusion (HAP)
Number of subjects: 22
Study: 15277171

Group type: EXPERIMENTAL
Intervention: Nutritional counseling to increase intake through diet and high-energy supplements
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard nutritional counseling (control group)
Number of subjects: 36
Study: 11271785

Group type: EXPERIMENTAL
Intervention: Topoisomerase II alpha and II beta expression assessment
Number of subjects: 177

Group type: COMPARATOR
Intervention: Established prognostic markers (WBC count, CD10 status, sex)
Number of subjects: 177
Study: 9544384

Group type: EXPERIMENTAL
Intervention: Thallium-201 (Tl-201)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Gallium-67 (Ga-67)
Number of subjects: 33
Study: 7826222

Group type: EXPERIMENTAL
Intervention: Ozagrel (400 mg/day) for 4 weeks, then DSCG (8 mg/day) for 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: DSCG (8 mg/day) for 4 weeks, then Ozagrel (400 mg/day) for 4 weeks
Number of subjects: 14
Study: 2979258

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lidamidine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30129080

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT) - 30 treatments of 100% oxygen at 2.4 ATA for 80 minutes
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment - 30 'sham' treatments, initially pressurized to 1.2 ATA, then cycled between 1.05–1.2 ATA for eight minutes before settling at 1.05 ATA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 28477432

Group type: EXPERIMENTAL
Intervention: Laparoscopic APR with trans-abdominal individualized levator transection (LAPR-TILT)
Number of subjects: 185
Study: 25592656

Group type: EXPERIMENTAL
Intervention: Levofloxacin inhalation solution (APT-1026)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 282
Study: 24018268

Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT) plus treatment-as-usual
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting-list control group (treatment-as-usual only)
Number of subjects: 39
Study: 21788905

Group type: EXPERIMENTAL
Intervention: Omocianine (0.1 mg/kg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Omocianine (all dose groups)
Number of subjects: 52
Study: 18234152

Group type: EXPERIMENTAL
Intervention: Phonological information during training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic information during training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phonological processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonological processing without meaning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both phonological and semantic processing
Number of subjects: 0
Study: 14722628

Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound device (HCU)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional transthoracic echocardiography (TTE)
Number of subjects: 55
Study: 10425820

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (N-AC) alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: N-acetylcysteine (N-AC) combined with activated charcoal (AC)
Number of subjects: 14
Study: 7484983

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Active placebo (diphenhydramine, 12.5 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluoxetine with detectable blood levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluoxetine with no detectable blood levels
Number of subjects: 45
Study: 2265137

Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 133

Group type: COMPARATOR
Intervention: Epirubicin 45 mg/m2 and Vindesine 3 mg/m2 on days 1 and 8 every 4 weeks
Number of subjects: 133
Study: 538812

Group type: EXPERIMENTAL
Intervention: Single injection of long-acting penicillin (Triplopen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Five-day course of crystalline and procaine penicillin
Number of subjects: 0
Study: 30204244

Group type: EXPERIMENTAL
Intervention: Tick‐E‐Vac vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EnceVir vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tick‐E‐Vac and EnceVir vaccines
Number of subjects: 0
Study: 28328712

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (25 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbohydrate supplementation (25 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Whey protein and Carbohydrate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Detraining (2 weeks)
Number of subjects: 20
Study: 26322904

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment of Insomnia (BBTI)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Information Control (IC)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: NREM delta power
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: NREM sigma power
Number of subjects: 77
Study: 24636714

Group type: EXPERIMENTAL
Intervention: TEVAR (Cook Zenith TX2)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 230
Study: 23627154

Group type: EXPERIMENTAL
Intervention: Stiletto needle
Number of subjects: 67

Group type: COMPARATOR
Intervention: Dichofenac Diethylammon
Number of subjects: 67
Study: 19416992

Group type: EXPERIMENTAL
Intervention: C reactive protein point of care testing
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Training in enhanced communication skills
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Combined intervention (C reactive protein testing and communication skills training)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 431
Study: 17302587

Group type: EXPERIMENTAL
Intervention: EC‐MPS 1080 mg bid
Number of subjects: 32

Group type: COMPARATOR
Intervention: MMF 1500 mg bid
Number of subjects: 32
Study: 15127325

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 11256540

Group type: EXPERIMENTAL
Intervention: Captopril plus 25 mg i.v. of canrenoate (1 mg/hour for the first 72 hours and then orally 25 mg/day)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Captopril alone (placebo)
Number of subjects: 187
Study: 10761243

Group type: EXPERIMENTAL
Intervention: Patients with psoriasis (PG I, No = 11)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with psoriasis (PG II, No = 27)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with psoriasis (PG I and PG II)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 38
Study: 8032582

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and codeine 30 mg in one combination tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and codeine 60 mg in one combination tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and codeine 30 mg in two separate tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and codeine 60 mg in two separate tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 24
Study: 2600323

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg every 12 hours for seven doses
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31972302

Group type: EXPERIMENTAL
Intervention: Mitral valve surgery in neonates/infants (n=64)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Mitral valve surgery in children (n=79)
Number of subjects: 143
Study: 30804129

Group type: EXPERIMENTAL
Intervention: Gefitinib at 250 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gefitinib plus bevacizumab at 15 mg/kg every 3 weeks
Number of subjects: 16
Study: 28039852

Group type: EXPERIMENTAL
Intervention: Incident delirium
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Restraining devices
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Hospital acquired conditions (HACs)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Other noxious insults
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: 90-day mortality
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Inverse probability weighted hazard of death due to delirium
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Mediation effect of potential mediators
Number of subjects: 469
Study: 26422724

Group type: EXPERIMENTAL
Intervention: Cigarettes containing 2.4 mg of nicotine per gram of tobacco
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Cigarettes containing 1.3 mg of nicotine per gram of tobacco
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Cigarettes containing 0.4 mg of nicotine per gram of tobacco
Number of subjects: 840

Group type: COMPARATOR
Intervention: Cigarettes containing 15.8 mg of nicotine per gram of tobacco
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual brand of cigarettes
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Cigarettes containing 5.2 mg of nicotine per gram of tobacco
Number of subjects: 840
Study: 24169161

Group type: EXPERIMENTAL
Intervention: wIRA (water-filtered infrared A irradiation) for 20 minutes preoperatively
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: wIRA (water-filtered infrared A irradiation)
Number of subjects: 400
Study: 21825096

Group type: EXPERIMENTAL
Intervention: UPPP combined with low‐temperature bipolar radiofrequency (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Submucosal minimally invasive lingual excision with radiofrequency (SMILE‐R; group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Submucosal minimally invasive lingual excision with a harmonic scalpel (SMILE‐H; group 3)
Number of subjects: 50
Study: 19438864

Group type: EXPERIMENTAL
Intervention: Skin care programme (2-hour training session and occupational advisory service)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 388
Study: 17519902

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (IV‐MO)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 25
Study: 15351192

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg once daily
Number of subjects: 3825

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3825
Study: 12714828

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (60-U/kg bolus and 12-U/kg/h infusion for 72 hours)
Number of subjects: 12142

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (not specified dosage)
Number of subjects: 12142
Study: 9639082

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors (SRIs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 40
Study: 8142329

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fermented Milk (FM)
Number of subjects: 6
Study: 2659136

Group type: EXPERIMENTAL
Intervention: High dose polyoestradiol phosphate (PEP) 160 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Daily low dose acetosalicylic acid (ASA) 75 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 200
Study: 5312233

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 25
Study: 31462261

Group type: EXPERIMENTAL
Intervention: Extended invitation highlighting benefits of early detection and prevention of lung disease (n=2194)
Number of subjects: 4407

Group type: COMPARATOR
Intervention: Standard invitation describing the content of the general health check (n=2213)
Number of subjects: 4407

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 4407
Study: 28833832

Group type: EXPERIMENTAL
Intervention: EtG-based contingency management (CM) intervention for alcohol abstinence and addiction treatment attendance for 12 weeks
Number of subjects: 40
Study: 26143297

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 18
Study: 23429161

Group type: EXPERIMENTAL
Intervention: Safety floors
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional institutional grade floor
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Safety floors (low BMI males)
Number of subjects: 30
Study: 21228137

Group type: EXPERIMENTAL
Intervention: Intranasal measles vaccine (Moraten)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subcutaneous measles vaccine (Moraten)
Number of subjects: 48
Study: 18304317

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 176

Group type: COMPARATOR
Intervention: Flat insoles
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Combined intervention of foot orthoses and physiotherapy
Number of subjects: 176
Study: 16723785

Group type: EXPERIMENTAL
Intervention: Pilsicainide (Pil) 150 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cibenzoline (Cib) 300 mg/day
Number of subjects: 60
Study: 15251867

Group type: EXPERIMENTAL
Intervention: Training program (ergometer cycling 30-40 min/day, including at least 20 min at 75% Vo(2 max), 5 days/week for 3 months)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sedentary schedule
Number of subjects: 14
Study: 11421998

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Domperidone (1 mg kg‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sulpiride (10 mg kg‐1)
Number of subjects: 12
Study: 9045280

Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8343611

Group type: EXPERIMENTAL
Intervention: Tolrestat
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Tolrestat (switched from placebo)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo (switched to tolrestat)
Number of subjects: 372
Study: 3511650

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 360

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 360
Study: 29680321

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (5 × 5 Gy plus 1 × 4 Gy boost)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy in 28 fractions plus 3 × 1.8 Gy boost and 5‐fluorouracil with leucovorin bolus)
Number of subjects: 51
Study: 27492908

Group type: EXPERIMENTAL
Intervention: Sedentary behavior intervention (eliminate all exercise and minimize steps to 5000 or less steps/d for 1 week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (continue normal physical activity levels for 1 week)
Number of subjects: 39
Study: 25549517

Group type: EXPERIMENTAL
Intervention: Intrusive force of 100 g delivered from mini-implants for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: No orthodontic treatment (control group)
Number of subjects: 16
Study: 23413535

Group type: EXPERIMENTAL
Intervention: Supportive educative nursing intervention incorporating blood pressure education, monitoring, goal setting and reinforcement.
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 118